Ceramides Mixture is an endogenous ceramide consisting of ceramides containing hydroxyl and non-hydroxy fatty acids. Ceramides Mixture is the major lipid component of the epidermal permeability barrier. Ceramides Mixture is involved in growth inhibition, cell cycle arrest and regulation of telomerase activity.

Physicochemical Properties

Molecular Formula	C46H82N2O23
Molecular Weight	1031.14288
Exact Mass	581.538
CAS #	100403-19-8
PubChem CID	57378373
Appearance	Off-white to light yellow solid powder
LogP	12.4
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	32
Heavy Atom Count	41
Complexity	568
Defined Atom Stereocenter Count	3
SMILES	CCCCCCCCCCCCC/C=C/[C@H]([C@H](COC1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3NC(=O)C)[C@H]2O)[C@H](O)[C@H]1O)NC(=O)C)O
InChi Key	ATGQXSBKTQANOH-UWVGARPKSA-N
InChi Code	InChI=1S/C36H71NO4/c1-3-5-7-9-11-13-15-17-18-19-21-23-25-27-29-31-35(40)37-33(32-38)36(41)34(39)30-28-26-24-22-20-16-14-12-10-8-6-4-2/h17-18,33-34,36,38-39,41H,3-16,19-32H2,1-2H3,(H,37,40)/b18-17-/t33-,34+,36-/m0/s1
Chemical Name	(Z)-N-[(2S,3S,4R)-1,3,4-trihydroxyoctadecan-2-yl]octadec-9-enamide
Synonyms	100403-19-8; N-(1,3,4-TRIHYDROXYOCTADECAN-2-YL)OCTADEC-9-ENAMIDE; RefChem:124459; Ceramide VI (AP); SCHEMBL29009460;
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	Endogenous metabolite
ln Vitro	In the A549 human lung cancer cell line, endogenous ceramide (generated by bacterial sphingomyelinase overexpression or daunorubicin therapy) suppresses telomerase reverse transcriptase mRNA production via deactivating the c-Myc transcription factor and telomerase activity[1]. The biochemical recycling of the sphingosine backbone of C6-ceramide is necessary for the continuous production of long-chain endogenous ceramides. This process entails the deacylation and reacylation of ceramides to produce endogenous long-chain ceramides, primarily C16:0- and C24:1-ceramide. The most likely source of these ceramides is CoA-dependent ceramide synthase, which fumonisin B1 inhibits. Long-chain endogenous ceramide synthesis in A549 cells mediates the effects of exogenous C6-ceramide on telomerase activity modulation, cell cycle arrest, and growth suppression [1].
References	[1]. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem. 2002 Apr 12;277(15):12960-9. [2]. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002 Jul;119(1):166-73.
Additional Infomation	N-oleoylphytosphingosine is a phytoceramide in which the N-acyl group is specified as oleoyl (9Z-octadecenoyl). It is functionally related to an oleic acid. Ceramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. Ceramide 3 consists of a phytosphingosine backbone N-acylated with a saturated fatty acid (stearic acid). It is widely used as a moisturizer in various cosmetic and personal products. Together with ceramide 1, they synergistically improve the skin barrier function in humans. See also: Ceramide 3 (annotation moved to).

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL H2O : ~33.33 mg/mL MEthanol : ~25 mg/mL

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 50 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	0.9698 mL	4.8490 mL	9.6980 mL
	5 mM	0.1940 mL	0.9698 mL	1.9396 mL
	10 mM	0.0970 mL	0.4849 mL	0.9698 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.